Assessment of Alcon's Ocular Image Quantification System

Status Completed

Clinical Trial Summary

The purpose of this study was to evaluate ocular responses with different allergen provocation methods.

Clinical Trial Description

Subjects demonstrating a successful allergen response to a common allergen received the first study treatment and used as instructed for 5 days, after which they entered the Environmental Exposure Chamber (EEC) for a 3-hour exposure to a known concentration of the allergen. After waiting at least 7 days, subjects received the second study treatment and used as instructed for 5 days, after which a 3-hour Conjunctival Allergen Provocation Test (CAPT) was performed with an escalating concentration of the allergen. Subjects dosed with study treatment approximately 15 minutes prior to each allergen provocation test. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01282138
Study type	Interventional
Source	Alcon Research
Contact
Status	Completed
Phase	Phase 4
Start date	December 2010
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03660878` - A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis	Phase 1/Phase 2
Completed	`NCT03682965` - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study	Phase 2
Completed	`NCT01697969` - Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT01685242` - A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle	Phase 3
Completed	`NCT01439815` - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo	Phase 4
Completed	`NCT01294969` - Patient Perception Study for AL-4943A	Phase 4
Completed	`NCT01471184` - The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo	Phase 1
Completed	`NCT00609128` - Effect of Olopatadine on Allergic Tear Mediators	N/A
Recruiting	`NCT05969236` - A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults	Phase 1
Active, not recruiting	`NCT04619017` - Airway Immune Response to Allergens (Use Lay Language Here)	Phase 1
Not yet recruiting	`NCT01012752` - A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts	Phase 3
Completed	`NCT01754766` - AGN-229666 for the Treatment of Allergic Conjunctivitis	Phase 2
Completed	`NCT01698814` - A Six-Week Safety Study of an Investigational Ophthalmic Solution	Phase 3
Completed	`NCT01443442` - Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis	Phase 4
Completed	`NCT01203540` - Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT00987272` - Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects	Phase 3
Completed	`NCT00769886` - Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.	Phase 3
Completed	`NCT00569777` - Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers	Phase 3
Completed	`NCT00586664` - Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis	Phase 3
Completed	`NCT00534794` - Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis	Phase 4